Clinical Trial

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Trial Details
NCT Number NCT06819215
Lead Sponsor Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Collaborators: Shandong Cancer Hospital and Institute
Conditions Cancer, Neoplasms, Neoplasms, Breast, Tumor, PARP, Ovarian Neoplasms, Prostatic Cancer, Pancreatic Cancer +3 more
Enrollment 188 participants
Start Date 2024-10-30
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-11